Lipofundin mediates major inhibition of intravenous propofol on phorbol myristate acetate and Escherichia coli-induced neutrophil extracellular traps

Mol Biol Rep. 2022 Jul;49(7):6517-6529. doi: 10.1007/s11033-022-07482-2. Epub 2022 May 30.

Abstract

Background: Neutrophil extracellular traps (NETs) consist of chromatin DNA networks that are studded with cytosolic and granular antimicrobial proteins to trap or kill an infected microorganism. A lipid emulsion, the solvent of pure propofol for intravenous application, is given to clinical patients who require intravenous feeding of fatty acids and fat for energy. Intravenous propofol is widely used to sedate critically ill patients. Both intravenous propofol and its lipid emulsion have immunomodulatory activity. However, the role of lipid emulsion of intravenous propofol on NET induction remains unclear.

Methods: In this study, neutrophils were stimulated with phorbol myristate acetate (PMA) or Escherichia coli (E. coli) in the absence or presence of intravenous propofol (Propofol-Lipuro®), its solvent lipid emulsion (Lipofundin) or pure propofol, and NETs were stained with SYTOX Green for visualization and quantification. Total HOCl was determined by measuring the taurine-chloramine complex, and intracellular HOCl was evaluated with BioTracker™ TP-HOCl 1 dye.

Results: PMA-induced NETs were not efficiently inhibited when Propofol-Lipuro® was added after PMA stimulation. Clinically relevant concentrations of Lipofundin exerted a significant reduction in PMA-induced NETs and total reactive oxidative species (ROS), which was comparable to that observed for Propofol-Lipuro®. Lipofundin transiently reduced intracellular HOCl production and the phosphorylation level of extracellular regulated kinase (p-ERK) but did not scavenge HOCl. Moreover, Lipofundin decreased E. coli-induced NETs in a ROS-independent pathway, similar to Propofol-Lipuro®.

Conclusions: All data agree that Lipofundin, the major component of Propofol-Lipuro®, inhibits intracellular HOCl and p-ERK to suppress PMA-induced NET formation but reduces E.coli-induced NETs in a ROS-independent pathway.

Keywords: E. coli; Hypochlorous acid; Intravenous propofol; Lipofundin; Neutrophil extracellular traps; Phorbol myristate acetate.

MeSH terms

  • Administration, Intravenous
  • Drug Combinations
  • Emulsions / administration & dosage
  • Escherichia coli* / immunology
  • Extracellular Signal-Regulated MAP Kinases
  • Extracellular Traps* / immunology
  • Humans
  • Hypochlorous Acid
  • Neutrophils* / immunology
  • Phospholipids* / pharmacology
  • Propofol* / administration & dosage
  • Propofol* / antagonists & inhibitors
  • Propofol* / pharmacology
  • Reactive Oxygen Species / metabolism
  • Solvents
  • Sorbitol* / pharmacology
  • Tetradecanoylphorbol Acetate* / pharmacology

Substances

  • Drug Combinations
  • Emulsions
  • Phospholipids
  • Reactive Oxygen Species
  • Solvents
  • Lipofundin
  • Sorbitol
  • Hypochlorous Acid
  • Extracellular Signal-Regulated MAP Kinases
  • Tetradecanoylphorbol Acetate
  • Propofol